Oncolytic Properties of a Mumps Virus Vaccine Strain in Human Melanoma Cell Lines

Ammour, Yulia; Ryabaya, Oxana; Milovanova, A. V.; Сидоров, Александр Викторович; Шохин, И. Е.; Zverev, V. V.; Nasedkina, T. V.

doi:10.1134/s0026893318040027

Cited by 12 publications

(20 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first clinical trials of Urabe MuV strain showed its oncolytic and immunotherapeutic potentials (5,(8)(9)(10). The results of preclinical studies have also shown that some natural and engineered MuV strains exhibit oncolytic activities against tumor cell lines in vitro and in vivo (7,(11)(12)(13)(14)(15)(16). The present study supports previous studies, where the oncolytic properties of other natural MuV vaccine strains were demonstrated against different human cancer cell lines, including melanoma (12), ovarian cancer (13), different solid malignancies (14), fibrosarcoma, adenocarcinoma (15), leukemia, and lymphoma (16).…”

Section: Discussionsupporting

confidence: 90%

“…This feature makes MuV a desirable candidate for the treatment of various cancers. Accordingly, different strains of MuV, derived from different isolates, have been examined as OVs (5,(7)(8)(9)(10)(11)(12)(13)(14)(15)(16).…”

Section: Discussionmentioning

confidence: 99%

“…Limited studies have been recently conducted in this area. More recently, however, some natural and chimeric MuV strains have been studied as potential anti-cancer agents (11)(12)(13)(14)(15)(16).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Intrinsic Oncolytic Activity of Hoshino Mumps Virus Vaccine Strain Against Human Fibrosarcoma and Cervical Cancer Cell Lines

et al. 2020

View full text Add to dashboard Cite

Background: The use of oncolytic viruses as therapeutic agents is a promising treatment for various human cancers. Several viruses have been extensively examined to achieve tumor cell death. Objectives: This study aimed at evaluating the natural oncolytic activity of mumps Hoshino vaccine strain against two human cancer cell lines, that is, HT1080 fibrosarcoma and HeLa cervical adenocarcinoma cell lines. Methods: The cytolytic activity of the virus was evaluated using an MTT assay. Apoptosis was detected by Annexin-V/propidium iodide (PI) staining and analyzed via flow cytometry. To indicate viral replication in vivo, nude mice with HeLa heterografts were treated with the Hoshino strain of mumps virus. Results: It was found that human fibrosarcoma and cervical cells were more sensitive to the mumps Hoshino strain, even at a very low multiplicity of infection (MOI) compared to normal human diploid cells. The results also showed that the Hoshino strain induced apoptosis in both cancer cells. A preliminary in vivo study revealed the significant suppression of tumor growth in the group treated with the mumps Hoshino strain compared to the control group. Conclusions: The Hoshino vaccine strain of mumps virus showed promising oncolytic activities against human fibrosarcoma and cervical adenocarcinoma cells.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Intrinsic Oncolytic Activity of Hoshino Mumps Virus Vaccine Strain Against Human Fibrosarcoma and Cervical Cancer Cell Lines

et al. 2020

View full text Add to dashboard Cite

show abstract

“…[22][23][24][25][26][27][28] In addition, virus-mediated oncolysis provides needful conditions for priming antitumor immunity by activation of tumorspecific cytotoxic T cells. 52,62,[82][83][84][85][86][105][106][107][108][109] To date, there are only three immunovirotherapies approved for use in human cancers, including the herpes simplex virus T-Vec, the modified adenovirus H101, and the picornavirus Rigvir, [110][111][112][113][114] even though many other OVs have been evaluated clinically. [29][30][31][32]40,[115][116][117][118] This is because the cost-intensive nature of manufacturing and testing clinal grade OVs make them far out of reach for most patients.…”

Section: Discussionmentioning

confidence: 99%

Repurposing Live Attenuated Trivalent MMR Vaccine as Cost-effective Cancer Immunotherapy

Nagalo¹,

Zhang

Taylor

et al. 2022

Preprint

View full text Add to dashboard Cite

Despite its rising promise, cancer immunotherapy remains out of reach for many patients because of the extensive cost of manufacturing immunotherapy products. In this study, we show that intratumoral injections of the trivalent measles, mumps, and rubella (MMR) live attenuated viral vaccine (LAVs) modulates a potent cytotoxic T-cell antitumor immune response, resulting in tumor growth inhibition and improved survival in syngeneic mouse models of hepatocellular carcinoma and colorectal cancer. Using an integrated transcriptomic and proteomic approach, we demonstrated that mechanistically, MMR exerts its antitumor activity by priming innate and adaptive antitumor immune responses, leading to immunologically coordinated cancer cells death. Our findings highlight a promising potential for LAVs, such as MMR, to be repurposed as cost-effective cancer immunotherapy.

show abstract

“…Previously, the oncolytic properties of the attenuated Russian vaccine strain of mumps virus "Leningrad-3" against human melanoma cells have been shown [12]. The aim of this study was to investigate the oncolytic potential of the attenuated Russian vaccine strain of measles virus "Leningrad-16" (L-16) against human melanoma cell lines and melanoma xenograft model.…”

Section: Introductionmentioning

confidence: 99%

The Susceptibility of Human Melanoma Cells to Infection with the Leningrad-16 Vaccine Strain of Measles Virus

Ammour

Ryabaya

Shchetinina

et al. 2020

Viruses

View full text Add to dashboard Cite

Oncolytic viruses, including live attenuated measles virus (MV) vaccine strains, have recently been shown as promising therapeutic agents against human malignancies. In this study, the oncolytic potential of the attenuated vaccine strain Leningrad-16 (L-16) of MV was evaluated in a panel of human metastatic melanoma cell lines. The L-16 measles virus was shown to replicate within melanoma cells mediating direct cell killing of tumor cells, although all melanoma cell lines varied in regard to their ability to respond to L-16 MV infection, as revealed by the different pattern of the Interferon Stimulated Gene expression, cytokine release and mechanisms of cell death. Furthermore, the statistically significant L-16 measles virus related tumor growth inhibition was demonstrated in a melanoma xenograft model. Therefore, L-16 MV represents an appealing oncolytic platform for target delivery of therapeutic genes along with other attenuated measles virus strains.

show abstract

Oncolytic Properties of a Mumps Virus Vaccine Strain in Human Melanoma Cell Lines

Cited by 12 publications

References 14 publications

Intrinsic Oncolytic Activity of Hoshino Mumps Virus Vaccine Strain Against Human Fibrosarcoma and Cervical Cancer Cell Lines

Intrinsic Oncolytic Activity of Hoshino Mumps Virus Vaccine Strain Against Human Fibrosarcoma and Cervical Cancer Cell Lines

Repurposing Live Attenuated Trivalent MMR Vaccine as Cost-effective Cancer Immunotherapy

The Susceptibility of Human Melanoma Cells to Infection with the Leningrad-16 Vaccine Strain of Measles Virus

Contact Info

Product

Resources

About